Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis

Nov 16, 2023World journal of diabetes

Comparing the effectiveness and safety of chiglitazar and thiazolidinedione in type 2 diabetes patients

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Ninety-three randomized controlled trials were analyzed to compare the efficacy and safety of chiglitazar and thiazolidinediones (TZDs) in patients with type 2 diabetes.

Chiglitazar resulted in a greater reduction in hemoglobin A1c levels by 0.15% compared to TZDs.
Chiglitazar also led to a more significant decrease in triglycerides by 0.17 mmol/L and alanine aminotransferase levels by 5.25 U/L compared to TZDs.
An increase in β-cell function, as measured by the homeostasis model assessment-β (HOMA-β), was observed with chiglitazar, showing a difference of 17.75.
Safety profiles for chiglitazar and TZDs were comparable, with no increased risks of hypoglycemia, edema, or fractures.
In patients with specific baseline characteristics, chiglitazar demonstrated more pronounced effects on HbA1c reduction and β-cell function improvement.

AI simplified

BACKGROUND: Chiglitazar is an emerging pan-agonist of all peroxisome proliferator activated receptors (PPAR)-α, δ and γ, and has therapeutic potential for type 2 diabetes (T2D). However, to date, no clinical studies or meta-analyses have compared the efficacy and safety of chiglitazar and traditional PPAR-γ agonist thiazolidinediones (TZDs). A meta-analysis concerning this topic is therefore required.

AIM: To compare the efficacy and safety of chiglitazar and TZD in patients with T2D.

METHODS: PubMed, Medline, Embase, the Cochrane Central Register of Controlled Trials,andwebsites were searched from August 1994 to March 2022. Randomized controlled trials (RCTs) of chiglitazar or TZDplacebo in patients with T2D were included. Indirect comparisons and sensitivity analyses were implemented to evaluate multiple efficacy and safety endpoints of interest. Reference Citation Analysis Clinicaltrial.gov vs

RESULTS: We included 93 RCTs that compared TZD with placebo and one that compared chiglitazar with placebo. For efficacy endpoints, the augmented dose of chig-litazar resulted in greater reductions in hemoglobin (Hb)A1c [weighted mean difference (WMD) = -0.15%, 95% confidence interval (CI): -0.27 to -0.04%], triglycerides (WMD = -0.17 mmol/L, 95%CI: -0.24 to -0.11 mmol/L) and alanine aminotransferase (WMD = -5.25 U/L, 95%CI: -8.50 to -1.99 U/L), and a greater increase in homeostasis model assessment-β (HOMA-β) (WMD = 17.75, 95%CI: 10.73-24.77) when compared with TZD treatment. For safety endpoints, the risks of hypoglycemia, edema, bone fractures, upper respiratory tract infection, urinary tract infection, and weight gain were all comparable between the augmented dose of chiglitazar and TZD. In patients with baseline HbA1c ≥ 8.5%, body mass index ≥ 30 kg/mor diabetes duration < 10 years, the HbA1c reduction and HOMA-β increase were more conspicuous for the augmented dose of chiglitazar compared with TZD. 2

CONCLUSION: Augmented dose of chiglitazar, a pan-activator of PPARs, may serve as an antidiabetic agent with preferable glycemic and lipid control, better β-cell function preserving capacity, and does not increase the risk of safety concerns when compared with TZD.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (HTML) ↗View full text ↗

Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief